| Lauren Lanier Guthrie, NP | |
|
102 Friars Cv, Clinton, MS 39056-3411 | |
| (601) 383-5583 | |
| Not Available |
| Full Name | Lauren Lanier Guthrie |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 102 Friars Cv, Clinton, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053962068 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 903581 (Mississippi) | Secondary |
| 363LA2100X | Nurse Practitioner - Acute Care | 903581 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Mississippi Med Center | Jackson, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State Of Mississippi - University Of Mississippi Medical Center | 1850293036 | 804 |
News Archive
Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.
One of the largest studies of its kind has found that people with coronary artery disease who have even a modest beer belly or muffin top are at higher risk for death than people whose fat collects elsewhere. The effect was observed even in patients with a normal Body Mass Index.
According to a new study by the Center for Studying Health System Change, the pattern isn't new but is picking up speed in the quest to increase market share and revenue.
The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan's 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches.
› Verified 9 days ago
| Entity Name | Medical Foundation Of Central Mississippi Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992774814 PECOS PAC ID: 1153216411 Enrollment ID: O20040217000380 |
News Archive
Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.
One of the largest studies of its kind has found that people with coronary artery disease who have even a modest beer belly or muffin top are at higher risk for death than people whose fat collects elsewhere. The effect was observed even in patients with a normal Body Mass Index.
According to a new study by the Center for Studying Health System Change, the pattern isn't new but is picking up speed in the quest to increase market share and revenue.
The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan's 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches.
› Verified 9 days ago
| Entity Name | State Of Mississippi - University Of Mississippi Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154317527 PECOS PAC ID: 1850293036 Enrollment ID: O20090414000575 |
News Archive
Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.
One of the largest studies of its kind has found that people with coronary artery disease who have even a modest beer belly or muffin top are at higher risk for death than people whose fat collects elsewhere. The effect was observed even in patients with a normal Body Mass Index.
According to a new study by the Center for Studying Health System Change, the pattern isn't new but is picking up speed in the quest to increase market share and revenue.
The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan's 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches.
› Verified 9 days ago
| Entity Name | Mississippi Baptist Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467589556 PECOS PAC ID: 9234026600 Enrollment ID: O20110707000181 |
News Archive
Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.
One of the largest studies of its kind has found that people with coronary artery disease who have even a modest beer belly or muffin top are at higher risk for death than people whose fat collects elsewhere. The effect was observed even in patients with a normal Body Mass Index.
According to a new study by the Center for Studying Health System Change, the pattern isn't new but is picking up speed in the quest to increase market share and revenue.
The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan's 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Lanier Guthrie, NP 102 Friars Cv, Clinton, MS 39056-3411 Ph: (601) 383-5583 | Lauren Lanier Guthrie, NP 102 Friars Cv, Clinton, MS 39056-3411 Ph: (601) 383-5583 |
News Archive
Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.
One of the largest studies of its kind has found that people with coronary artery disease who have even a modest beer belly or muffin top are at higher risk for death than people whose fat collects elsewhere. The effect was observed even in patients with a normal Body Mass Index.
According to a new study by the Center for Studying Health System Change, the pattern isn't new but is picking up speed in the quest to increase market share and revenue.
The American College of Rheumatology has launched its Simple Tasks campaign. The initiative aims to raise awareness of the severe impact of rheumatic diseases - such as rheumatoid arthritis, lupus and gout - on the U.S. population and to highlight the importance of rheumatologists in the diagnosis and treatment of these diseases.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan's 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches.
› Verified 9 days ago
Mrs. Lakeisha Crye Green, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 901 Highway 80 E, Clinton, MS 39056 Phone: 601-488-9668 | |
Ms. Barbara Ann Bradley, CFNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1407 Beverly Dr, Clinton, MS 39056 Phone: 601-575-3392 | |
Mrs. Amanda Monique Carson-griffin, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 590 Springridge Rd, Clinton, MS 39056 Phone: 601-488-8101 | |
Alexis Grabow Strahan, MSN, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 106 Clinton Pkwy, Clinton, MS 39056 Phone: 601-924-9005 | |
Elizabeth Clark Allen, CFNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 728 Clinton Pkwy Ste B, Clinton, MS 39056 Phone: 601-200-4800 Fax: 601-200-4805 | |
Jennifer Russum, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 732 Clinton Pkwy, Clinton, MS 39056 Phone: 601-924-7994 |